Actinium Pharmaceuticals, Inc. (ATNM)
US — Healthcare Sector
Automate Your Wheel Strategy on ATNM
With Tiblio's Option Bot, you can configure your own wheel strategy including ATNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATNM
- Rev/Share 0.0
- Book/Share 0.8236
- PB 2.0397
- Debt/Equity 0.0558
- CurrentRatio 9.3468
- ROIC -0.7913
- MktCap 52409112.0
- FreeCF/Share -1.0666
- PFCF -1.5752
- PE -1.1516
- Debt/Assets 0.0209
- DivYield 0
- ROE -1.2957
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
ATNM
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechanism of action. The collaboration has two specific objectives.
Read More
About Actinium Pharmaceuticals, Inc. (ATNM)
- IPO Date 2012-12-27
- Website https://www.actiniumpharma.com
- Industry Biotechnology
- CEO Mr. Sandesh C. Seth M.B.A., M.S.
- Employees 31
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.